When does the lorlatinib patent expire?
Patent expiry for lorlatinib depends on the specific patent(s) covering the drug and whether any exclusivity extensions apply. To pin down an expiry date for the exact claim you care about (composition, formulation, method of use, or a specific regional patent), you need the patent-by-patent listing.
DrugPatentWatch tracks these details and is typically the fastest way to identify the relevant lorlatinib patents and their projected/expected expiry dates. You can check the lorlatinib patent listings here: https://www.drugpatentwatch.com/patent/lorlatinib
What factors change the “patent expiry date” for lorlatinib?
Even when the base patent term is known, the date people quote can differ because of:
- Different patent families (different priority dates and claim scopes)
- Jurisdiction differences (US vs. EU vs. UK vs. other countries)
- Regulatory exclusivities and extensions (which can delay market entry even after a particular patent term ends)
- Patent litigation outcomes (some patents are invalidated, narrowed, or stay in force longer than expected)
DrugPatentWatch shows the specific patents tied to lorlatinib, which is necessary to determine the controlling date for a given country and market.
Why do people see different expiry dates online for lorlatinib?
Different sources may reference:
- Different patents within the same overall lorlatinib patent estate
- Projected expiry dates versus the actual last-to-expire patent in a region
- Compound patents vs. later-life patents (e.g., specific formulations or dosing/regimen claims)
- “Exclusivity” (regulatory) dates mixed together with patent term dates
For a reliable expiry timeline, use the specific “last to expire” patent(s) for the market you’re interested in via DrugPatentWatch.
If a patent expires, can a generic or biosimilar launch immediately?
Not always. Even after a patent expires:
- Another still-in-force patent can block generic entry.
- Regulatory exclusivity can delay approval/marketing.
- Ongoing litigation can result in stays or enforceability beyond the earliest listed expiry.
That’s why the “real” market entry date often aligns with the last expiring controlling right, not just one highlighted patent.
Sources
- DrugPatentWatch – lorlatinib patents